November 2015

New Product - Ofev

Ofev (nintedanib esilate) is a triple angiokinase inhibitor, blocking vascular endothelial growth factor receptors (VEGFR 1-3), platelet derived growth factor receptors (PDGFR α and β) and fibroblast growth factor receptor (FGFR 1-3) kinase activity. Ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after failure of first line chemotherapy. Ofev is also indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is contraindicated during pregnancy. Ofev is available as 100 mg and 150 mg capsules in packs of 60’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au